|Conditional recommendation based on very-low-quality evidence; may consider MTX and an IL-12/23i biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, or has concomitant uveitis (since uveitis may respond to MTX therapy).|Conditional recommendation based on very-low-quality evidence; may consider MTX and an IL-12/23i biologic combination therapy if the patient has severe skin manifestations, has had a partial response to